Cited by Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: A network meta‐analysis of randomized controlled trials

From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need DOI

Michail Kokkorakis, Chrysoula Boutari, Niki Katsiki

et al.

Metabolism, Journal Year: 2023, Volume and Issue: 147, P. 155664 - 155664

Published: July 28, 2023

Language: Английский

Citations

Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment DOI

Norbert Stefan, Hannele Yki‐Järvinen, Brent A. Neuschwander‐Tetri

et al.

The Lancet Diabetes & Endocrinology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 1, 2024

Language: Английский

Citations

Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease DOI

Violeta Raverdy, Federica Tavaglione,

Estelle Chatelain

et al.

Nature Medicine, Journal Year: 2024, Volume and Issue: 30(12), P. 3624 - 3633

Published: Dec. 1, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) exhibits considerable variability in clinical outcomes. Identifying specific phenotypic profiles within MASLD is essential for developing targeted therapeutic strategies. Here we investigated the heterogeneity of using partitioning around medoids clustering based on six simple variables a cohort 1,389 individuals living with obesity. The identified clusters were applied across three independent cohorts biopsy (totaling 1,099 participants), and UK Biobank to assess incidence chronic disease, cardiovascular type 2 diabetes. Results unveiled two distinct types associated steatohepatitis histology imaging. first cluster, liver-specific, was genetically linked showed rapid progression but limited risk disease. second cardiometabolic, primarily dysglycemia high levels triglycerides, leading similar higher Analyses samples from 831 available transcriptomics 1,322 plasma metabolomics highlighted that these exhibited transcriptomic metabolomic signatures, respectively. In conclusion, data provide preliminary evidence existence clinically relevant phenotypes at baseline, each underlying biological different trajectories, suggesting need tailored Partitioning multiple patient identifies subtypes metabolic associations hepatic

Language: Английский

Citations

Prevalence and risk factors of MAFLD and its metabolic comorbidities in community-based adults in China: A cross-sectional study DOI

Yajun He,

Nanfang Yao,

Feng Tian

et al.

Diabetes & Metabolic Syndrome Clinical Research & Reviews, Journal Year: 2024, Volume and Issue: 18(3), P. 102973 - 102973

Published: March 1, 2024

Language: Английский

Citations

Metabolic Dysfunction Associated-Steatotic Liver Disease (MASLD) and Cardiovascular Risk: Embrace All Facets of the Disease DOI

Niki Katsiki, Genovefa Kolovou, Michal Vrablı́k

et al.

Current Cardiology Reports, Journal Year: 2025, Volume and Issue: 27(1)

Published: Jan. 13, 2025

Language: Английский

Citations

Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians DOI

Tingfeng Wu,

Junzhao Ye,

Sui-Lin Mo

et al.

Journal of Gastroenterology and Hepatology, Journal Year: 2024, Volume and Issue: 39(8), P. 1636 - 1647

Published: May 2, 2024

Abstract Background and Aim The introduction of the latest nomenclature, metabolic associated steatotic liver disease (MASLD), proposed by multi‐society without Asian society consensus statement, aims to redefine diagnostic criteria for fatty (MAFLD). However, its effect on epidemiology in Asia remains unclear. Method We conducted a population‐based cross‐sectional survey using multistage stratified random sampling participants from Guangzhou, representative area China (ChiCTR2000033376). Demographic, socioeconomic, lifestyle, laboratory data were collected. Hepatic steatosis severity fibrosis assessed FibroScan. Results A total 7388 individuals recruited, proportion which meeting definitions nonalcoholic (NAFLD), MAFLD, MASLD 2359 (31.9%), 2666 (36.1%), 2240 (30.3%), respectively. One hundred twenty (1.6%) patients had cryptogenic SLD, 537 (7.3%) diagnosed with MetALD. did not significantly differ NAFLD except that MAFLD lower males, hypertension, diabetes less likely consume tea ( P < 0.05). Both SLD non‐MAFLD exhibited milder hepatic frequency injury than NAFLD, or (all An increased HOMA‐IR (adjusted OR: 1.33, 95% CI: 1.10–2.03) was higher risk moderate‐to‐severe patients, while consuming more cups trend = 0.015) showed inverse associations. Conclusion Irrespective terminology used is highly prevalent Han Chinese population. Differences insulin resistance lifestyle factors are redefinition disparities.

Language: Английский

Citations

Liver fat as risk factor of hepatic and cardiometabolic diseases DOI

Münevver Demir, Stefan R. Bornstein, Christos S. Mantzoros

et al.

Obesity Reviews, Journal Year: 2023, Volume and Issue: 24(10)

Published: Aug. 8, 2023

Summary Non‐alcoholic fatty liver disease (NAFLD) is a disorder characterized by excessive accumulation of fat in the that can progress to inflammation (non‐alcoholic steatohepatitis [NASH]), fibrosis, and cirrhosis. Although most efforts for drug development are focusing on treatment latest stages NAFLD, where significant fibrosis NASH present, findings from studies suggest amount may be an important independent risk factor and/or predictor progression NAFLD metabolic diseases. In this review, we first describe current tools available quantification humans then present clinical pathophysiological evidence link with as well cardiometabolic Finally, discuss pharmacological non‐pharmacological approaches reduce open questions have addressed future studies.

Language: Английский

Citations

AKR1B1 drives hyperglycemia-induced metabolic reprogramming in MASLD-associated hepatocellular carcinoma DOI

Syamprasad NP, Siddhi Jain, Bishal Rajdev

et al.

JHEP Reports, Journal Year: 2023, Volume and Issue: 6(2), P. 100974 - 100974

Published: Nov. 28, 2023

Background & AimsThe mechanism behind the progressive pathological alteration in MASLD/MASH-associated HCC is poorly understood. In present study, we have investigated role of polyol pathway enzyme, AKR1B1 metabolic switching associated with MASLD/MASH and progression HCC.MethodsThe expression tissue plasma patients MASLD/MASH, HCC, diabetes mellitus were estimated. The vitro was assessed through media conditioning, lentiviral transfection, pharmacological probes. proteomic metabolomic approach applied for in-depth investigation pathway. Preclinically, a high fructose diet (HFrD) diethyl nitrosamine (DEN) induced mouse model developed to investigate hyperglycemia-mediated pathobiology MASLD-HCC.ResultsA significant increase observed HCC-DM samples compared normal samples. Mechanistically, vitro, assays revealed that modulates Warburg effect, mitochondrial dynamics, TCA cycle, lipogenesis promote MASLD cancer progression. A pathologically increased experimental MASLD-HCC, positively correlated blood glucose levels. HFrD+DEN-treated animals also exhibited statistically elevation markers carcinogenesis markers. However, inhibition EPS or NARI-29 has inhibited cellular metabolism vivo models.ConclusionsPathological hepatic MASLD-associated hepato-carcinogenesis. Aldose reductase glycolytic prevent pre-cancerous hepatocyte formation.Impact ImplicationsThe research work vitalizes as druggable target MASH/MASLD which will provide base developing new chemotherapeutic agents. Moreover, study implicates use levels prognostic marker diagnostic test HCC. Additionally, major observation promotion effect

Language: Английский

Citations

Novel metabolic phenotypes for extrahepatic complication of nonalcoholic fatty liver disease DOI

Jiayi Yi, Lili Wang, Jiajun Guo

et al.

Hepatology Communications, Journal Year: 2023, Volume and Issue: 7(1), P. e0016 - e0016

Published: Jan. 1, 2023

Background and Aims: Phenotypic heterogeneity among patients with NAFLD is poorly understood. We aim to identify clinically important phenotypes within assess the long-term outcomes different phenotypes. Methods: analyzed clinical data of 2311 participants from Third National Health Nutrition Examination Survey (NHANES III) their linked mortality through December 2019. was diagnosed by ultrasonographic evidence hepatic steatosis without other liver diseases excess alcohol use. A 2-stage cluster analysis applied used Cox proportional hazard models explore all-cause cause-specific between clusters. Results: identified 3 Cluster 1 characterized young female better metabolic profiles lower prevalence comorbidities; 2 obese females significant insulin resistance, diabetes, inflammation, advanced fibrosis male hypertension, atherogenic dyslipidemia, kidney damage. In a median follow-up 26 years, 989 (42.8%) occurred. presented best prognosis, whereas had higher risks (Cluster 2—adjusted HR: 1.48, 95% CI: 1.16–1.90; 3—adjusted 1.29, 1.01–1.64) cardiovascular 2.01, 1.18–3.44; 1.75, 1.03–2.97) mortality. Conclusions: Three phenotypically distinct meaningful subgroups have been characteristics profiles. This study reveals substantial disease that exists underscores need for granular assessments define improve practice.

Language: Английский

Citations

Investigation about the correlation between the severity of metabolic-associated fatty liver disease and adherence to the Mediterranean diet DOI

Marjan Mokhtare,

Arman Abdi,

Amir M. Sadeghian

et al.

Clinical Nutrition ESPEN, Journal Year: 2023, Volume and Issue: 58, P. 221 - 227

Published: Oct. 7, 2023

Language: Английский

Citations